299 related articles for article (PubMed ID: 16842135)
1. Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Kakafika AI; Liberopoulos EN; Karagiannis A; Athyros VG; Mikhailidis DP
Curr Vasc Pharmacol; 2006 Jul; 4(3):175-83. PubMed ID: 16842135
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia in the metabolic syndrome in children.
Gidding SS
J Cardiometab Syndr; 2006; 1(4):282-5. PubMed ID: 17679808
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
Nakajima K
Curr Clin Pharmacol; 2010 May; 5(2):133-9. PubMed ID: 20156152
[TBL] [Abstract][Full Text] [Related]
5. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
6. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
7. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
8. [How to treat dyslipidemia in patients with metabolic syndrome].
Soška V
Vnitr Lek; 2015; 61(7-8):721-4. PubMed ID: 26375703
[TBL] [Abstract][Full Text] [Related]
9. The lipid triad, or how to reduce residual cardiovascular risk?
Girard-Mauduit S
Ann Endocrinol (Paris); 2010 Mar; 71(2):89-94. PubMed ID: 20303470
[TBL] [Abstract][Full Text] [Related]
10. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease.
Matsuo Y; Hashizume T; Shioji S; Akasaka T
Circ J; 2008 Dec; 72(12):2046-50. PubMed ID: 18946171
[TBL] [Abstract][Full Text] [Related]
12. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
Windler E; Schöffauer M; Zyriax BC
Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448
[TBL] [Abstract][Full Text] [Related]
13. Atherogenic dyslipidemia in the cardiometabolic syndrome.
Govindarajan G; Chowdhury N; Flaker G
J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
[No Abstract] [Full Text] [Related]
14. Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.
Bosomworth NJ
Can Fam Physician; 2013 Nov; 59(11):1169-80. PubMed ID: 24235189
[TBL] [Abstract][Full Text] [Related]
15. Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
Ballantyne CM
Clin Cornerstone; 2007; 8 Suppl 6():S6-13. PubMed ID: 17948362
[TBL] [Abstract][Full Text] [Related]
16. Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome.
Robins SJ
Curr Cardiol Rep; 2005 Nov; 7(6):457-64. PubMed ID: 16256016
[TBL] [Abstract][Full Text] [Related]
17. Fibrates: where are we now?
Seth Loomba R; Arora R
Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
[TBL] [Abstract][Full Text] [Related]
18. [Lipid management--treatment goal and strategy].
Koshiyama H
Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
Robins SJ
Curr Opin Lipidol; 2003 Dec; 14(6):575-83. PubMed ID: 14624134
[TBL] [Abstract][Full Text] [Related]
20. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
Basile J; Houston M; Ferrario CM
J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
[No Abstract] [Full Text] [Related]
[Next] [New Search]
